Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

Trial Profile

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evinacumab (Primary) ; Evinacumab (Primary)
  • Indications Dyslipidaemias; Hypertriglyceridaemia
  • Focus Adverse reactions; First in man
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 27 Jun 2019 Results from two phase I studies of evinacumab (SAD and MAD studies) published in the Circulation
    • 24 May 2017 Results for Group A (n=83), published in the New England Journal of Medicine
    • 24 May 2017 Results published in the New England Journal of Medicine, according to a Regeneron Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top